Soleno Therapeutics, Inc.
SLNO
$65.60
$2.864.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.49% | -21.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.98% | -27.24% | |||
| Operating Income | 87.32% | 27.24% | |||
| Income Before Tax | 89.24% | 21.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 89.24% | 21.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 89.24% | 21.81% | |||
| EBIT | 87.32% | 27.24% | |||
| EBITDA | 88.36% | 27.47% | |||
| EPS Basic | 90.16% | 25.63% | |||
| Normalized Basic EPS | 91.91% | 30.26% | |||
| EPS Diluted | 90.16% | 25.63% | |||
| Normalized Diluted EPS | 91.91% | 30.26% | |||
| Average Basic Shares Outstanding | 9.32% | 5.13% | |||
| Average Diluted Shares Outstanding | 9.32% | 5.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||